TY  - JOUR
AU  - Schmidt, Claudia C
AU  - Bardakan, Michella M
AU  - Jaeger, Elena
AU  - Richter, Nils
AU  - Bischof, Gérard N
AU  - Giehl, Kathrin
AU  - Onur, Oezguer A
AU  - Jessen, Frank
AU  - Fink, Gereon R
AU  - Drzezga, Alexander
AU  - Weiss, Peter H
TI  - Apraxic deficits predict general cognitive impairment in patients with biomarker-verified Alzheimer's pathology.
JO  - Journal of neurology
VL  - 272
IS  - 10
SN  - 0367-004X
CY  - [Darmstadt]
PB  - Steinkopff
M1  - DZNE-2025-01126
SP  - 654
PY  - 2025
AB  - Apraxia represents a core feature of Alzheimer's disease (AD), a neurodegenerative disorder characterised by the accumulation of β-amyloid plaques and tau deposition. However, systematic descriptions of apraxic deficits in AD patients remain scarce. Here, we comprehensively investigate apraxia profiles and their link with cognitive impairment in patients with biomarker-verified Alzheimer's pathology. We characterised the frequency and patterns of apraxic deficits in patients with biomarker-verified Alzheimer's pathology using a battery of standardised apraxia tests. Demographic variables and apraxia scores were related to patients' general cognitive impairment using hierarchical regression analysis. Apraxic deficits were found in 67
KW  - Humans
KW  - Alzheimer Disease: complications
KW  - Alzheimer Disease: pathology
KW  - Alzheimer Disease: psychology
KW  - Alzheimer Disease: diagnosis
KW  - Female
KW  - Male
KW  - Aged
KW  - Apraxias: etiology
KW  - Apraxias: diagnosis
KW  - Cognitive Dysfunction: diagnosis
KW  - Cognitive Dysfunction: etiology
KW  - Biomarkers
KW  - Aged, 80 and over
KW  - Neuropsychological Tests
KW  - Middle Aged
KW  - Gestures
KW  - Alzheimer’s disease (Other)
KW  - Gesture imitation (Other)
KW  - Limb apraxia (Other)
KW  - Mini-Mental State Examination (MMSE) (Other)
KW  - Pantomime (Other)
KW  - Biomarkers (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40999034
C2  - pmc:PMC12464036
DO  - DOI:10.1007/s00415-025-13401-9
UR  - https://pub.dzne.de/record/281505
ER  -